$CCXI News

Last published 1w ago

1w agoAGLT CCXIAgility Robotics and Churchill Capital Corp XI Complete Business CombinationGlobeNewswireAgility to Become the Only U.S. Publicly Listed Pure-Play Humanoid Robotics Company with Proven, Active Commercial Deployments Shares Expected to Begin Trading on Nasdaq Under "AGLT" on November 5, 2026 SALEM,
1w agoCCXIChurchill Capital Corp XI Shareholders Approve Business Combination with Agility RoboticsGlobeNewswireApproximately $465 million in expected gross capital to support Agility’s business plan and accelerate commercial deployments Transaction expected to close on November 4, 2026; combined company expected to begin
1w agoCCXIAgility Robotics and Churchill Capital Corp XI Announce Expected Gross Capital Raise of Approximately $465 Million and Anticipated Closing of Business CombinationGlobeNewswireBusiness combination expected to close on November 4, 2026, subject to Churchill XI shareholder approval; the combined company expected to begin trading on Nasdaq under ticker symbol "AGLT" on November 5, 2026.
2w agoCCXIAgility Robotics Highlights Commercial Momentum and Growing Enterprise Demand for Digit Humanoid RobotGlobeNewswireGXO Expanding to Two Additional Facilities; Three Additional Manufacturing Customers and 30+ Prospective Customers Highlight New Opportunities in Manufacturing, Automotive, Logistics and Defense CEO Peggy Johnson to
2w agoGXO CCXIGXO and Agility Robotics Expand Partnership to Accelerate Deployment of Humanoids in U.S. OperationsGlobeNewswireDigit humanoid robots to expand to additional GXO sites in 2027, building on industry-first Robots-as-a-Service agreement GREENWICH, Conn. and Salem, Ore., Oct. 26, 2026 (GLOBE NEWSWIRE) -- GXO Logistics, Inc.
2w agoCCXIAgility Robotics Expands NVIDIA Collaboration as It Prepares Digit 5 for Commercial ScaleGlobeNewswireSALEM, Ore., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Agility Robotics, a leading humanoid robotics and physical AI company, today announced that Digit® 5 will standardize on NVIDIA IGX Thor for its onboard compute,
3w agoCCXIAgility Robotics Expands Pittsburgh Presence to Support Growing Customer DeploymentsGlobeNewswireNew 50,000-Square-Foot Facility Will Expand Agility’s Deployment, Service, Software and AI Capabilities Company Adds Four Customers Across Automotive, Consumer Goods and Agriculture PITTSBURGH , Oct. 21, 2026
3w agoAGCO CCXIAGCO and Agility Robotics Advance Smart Manufacturing with Humanoid Robot Pilot in Hesston, Kansas, FacilityGlobeNewswireAgility Robotics’ Digit humanoid robot is designed to perform repetitive, physically demanding tasks in human-centric work environments. AGCO plans to pilot Digit at its Hesston, Kansas, manufacturing facility
3w agoCCXIAgility Robotics Announces Audit Committee Chair for Planned Public-Company BoardGlobeNewswireSALEM, Ore. and NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Agility Robotics, a leading humanoid robotics and physical AI company, today announced that Mark Vale, CEO and board member at Transportation Insight and a
3w agoAGLT CCXIAgility Robotics Selects Nyobolt as its Ultra-Fast Charging Battery Technology Partner for Digit 5PR NewswireNyobolt's Battery Technology Enables Digit 5 to Work More Than 20 Hours in a 24-hour Day SALEM, Ore. and CAMBRIDGE, United Kingdom, Oct. 15, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and
4w agoCCXIAgility Robotics and Churchill Capital Corp XI S-4 Registration Statement Declared Effective by SEC in Connection with Proposed Business CombinationBusiness WireChurchill XI has set a shareholder meeting date of November 2, 2026 to approve the proposed business combination and related matters. Transaction expected to create the only U.S. publicly listed pure-play humanoid
1mo agoCCXIAgility Robotics to Livestream Analyst & Investor Day TodayBusiness WireEvent to Feature Digit 5, Agility’s Scaling Strategy and Perspectives From Schaeffler, Foxconn and AUVSI Agility Robotics, a leading humanoid robotics and physical AI company, will host its Analyst & Investor Day
1mo agoCCXIAgility Robotics Announces New Directors for Planned Public-Company BoardBusiness WireTechnology, Business and Legal Leaders Bring Decades of Experience in Global Commercialization, Strategic Partnerships and Corporate Governance as Agility Prepares to Scale Humanoid Robotics Agility Robotics, a
1mo agoCCXIAgility to Host Analyst & Investor Day on October 6, 2026Business WireLeadership to Discuss Digit 5, Commercial Momentum, Technology Roadmap, Scaling Strategy and Long-Term Financial Opportunity Agility Robotics, a leading humanoid robotics and physical AI company, today announced that
1mo agoCCXIAgility Unveils Digit 5 Humanoid Robot Built for Cooperatively Safe Work at ScalePR NewswireAgility Robotics, a leading humanoid robotics and physical AI company, today unveiled Digit® 5, the next generation of its general-purpose humanoid...
2mo agoCCXIAgility Robotics to Attend Upcoming Investor ConferencesBusiness WireAgility Robotics, a leading humanoid robotics and Physical AI company, today announced that the Company will be attending the following investor conferences through the end of the third quarter: Citi Global TMT
3mo agoCCXI NRGVAgility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial OfficerPR NewswireAgility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as...
3mo agoCCXIAgility Opens New Fremont Facility to Accelerate Physical AI DevelopmentPR NewswireAgility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to...
4mo agoCCXIAgility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business CombinationBusiness WireTransaction Expected to Create The Only Publicly Listed Pure-Play Humanoid Company with Proven, Active Commercial Deployments Agility Robotics, Inc. ("Agility" or the "Company") creator of the
4mo agoCCXIAgility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XIBusiness WireTransaction expected to create the only U.S. publicly listed pure-play humanoid company with proven, active commercial deployments Operating today in commercial environments with leading enterprises including
9mo agoCCXI CCXIUChurchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026GlobeNewswireNew York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (NASDAQ:CCXIU) (the "Company") announced today that, commencing February 9, 2026, holders of the units sold in the Company's initial public
2y agoCCXIApproval of Tavneos, Nda #214487 (Labeling)FDA Approved DrugsApproval Date: 06/03/2024; Drug Name: Tavneos, Nda #214487; Active Ingredients: AVACOPAN; Company: Chemocentryx; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214487
4y agoAMGN CCXIAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXPR NewswireTAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
4y agoCCXIChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsGlobeNewswire-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover
4y agoCCXIChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswire-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCe
4y agoCCXIChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesGlobeNewswireSAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an o
4y agoAMRS IFF SCHW CCXI+6Cramer's lightning round: Charles Schwab is terrificCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
4y agoCCXIChemoCentryx Cancels Second Quarter 2022 Financial Results Conference CallGlobeNewswireSAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is b
4y agoAMGN CCXIAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASHPR NewswireAcquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4,
4y agoCCXIChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent DirectorGlobeNewswireSAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board incre
4y agoCCXIChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CA
4y agoCCXIChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology ConferencesGlobeNewswireSAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered
4y agoCCXIChemoCentryx Announces Changes to its Board of DirectorsGlobeNewswire-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced changes to t
4y agoCCXIChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis SuppurativaGlobeNewswire-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.,
4y agoCCXIChemoCentryx to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireSAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, Ma
4y agoCCXIChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated VasculitisGlobeNewswireSAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the ap
4y agoCCXI DKNG ENSV ONEM+1Thinking about buying stock in Draftkings, ChemoCentryx, Opendoor Technologies, 1life Healthcare, or Enservco Corp?PR NewswireNEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, CCXI, OPEN, ONEM, and ENSV. To
4y agoCCXIChemoCentryx Reports First Quarter 2022 Financial Results and Recent HighlightsGlobeNewswire-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique
4y agoCCXIChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022GlobeNewswireSAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive manag
4y agoCCXIChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewswire-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients -- SAN CAR
4y agoCCXIChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewswire-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS
4y agoCCXIChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022GlobeNewswireMOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentr
4y agoCCXIChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Heal
4y agoCCXIChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated VasculitisGlobeNewswire-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclop
4y agoCCXIChemoCentryx to Present at Two Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan
5y agoCCXIPositive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)GlobeNewswireSAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketin
5y agoCCXIChemoCentryx to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: Stifel 2021 Virtual
5y agoCCXIChemoCentryx Reports Third Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan; European CHMP opinion expected this month -- -- Pipelin
5y agoCCXIChemoCentryx, inc (CCXI) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsCCXI earnings call for the period ending September 30, 2021.
5y agoCCXIAbstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)GlobeNewswireSAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021